Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis. J Gastroenterol Hepatol. 2016;31:716-726.Ichikawa H, Sugimoto M, Sugimoto K, Andoh A, Furuta T. Rapid metabolizer genotype of CYP2C19 is a risk factor of being ...
cyp2c19奥美拉唑amoxi阿莫西林浓度-omeprazole.pdf,CYP2C19: Omeprazole Amoxi: amoxicillin, AUC: Area under the concentrationtime curve, BID: twice a day, CI: confidence interval, Clari: clarithromycin, Clor: oral clearance, EM: extensive metabolizer (*1/*1,
CYP2C19 Phenotype, Stent Thrombosis, Myocardial Infarction, and Mortality in Patients with Coronary Stent Placement in a Chinese Population DOI: 10.1371/journal.pone.0059344 Xiang Xie, Yi-Tong Ma, Yi-Ning Yang, Xiao-Mei Li, Xiang Ma, Zhen-Yan Fu, Ying-Ying Zheng, Bang-Dang Chen, Fen Liu ...
Thus, we analysed the alleles CYP2C19*2, CYP2C19*3, CYP2C19*4 and CYP2C19*5 related to the poor metabolizer (PM) phenotype in a Mexican population sample ( n = 238), as well as CYP2C19*17 , unique allele related to ultrarapid metabolizer phenotype (UMs). Genotypes were determined using ...
Polymorphisms in CYP2D6 alleles and their influence on the metabolic activity of CYP2D6 in a duplication-negative individuals with the ultrarapid metabolizer healthy Chinese population. Clin Pharmacol Ther, 2007, 81(1):95-98. phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
A significant portion of extensive metabolizers do not reach appropriate drug levels, and our objective was to investigate any genetic background. METHODS: The 5'-flanking region of the CYP2C19 gene from subjects with rapid omeprazole metabolism was sequenced, and CYP2C19 phenotype-genotype ...
(1999). "An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians.". Pharmacogenetics 8 (2): 129-35. PMID 10022751. Foster DJ, Somogyi AA, Bochner F (1999). "Methadone N-demethylation in human liver microsomes: lack of stereoselectiv...
Ultra rapid metabolizers Extensive metabolizers Intermediate metabolizers Poor metabolizers After: personalized medicine (from genotype to phenotype) 500 mg 100 mg 10 mg UM EM IM PM 4P型个体化医学 个体化医学是根据个体对特定疾病的易感性的基因变异而施行的 早期预警、预防和一旦发病后根据药物相关基因的...
Inclusion ofCYP2C19*4reclassified individuals from either extensive- or intermediate- to the intermediate- or poor-metabolizer phenotypes, respectively. Inclusion of the redefinedCYP2D6*41Aallele increased the ultrarapid-, intermediate- and poor-metabolizer phenotype combined frequencies to 30%, indicating ...
The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles.###Prediction of in vivo clearance and associated variability of CYP2C19 substrates by genotypes in populations utilizing a pharmacogenetics-...